Mölnlycke and Ondine Unite to Fight Hospital Infections
Mölnlycke Health Care has launched an innovative partnership with Ondine Biomedical Inc. to strengthen their efforts against healthcare-associated infections (HAIs). This collaboration will focus on distributing Ondine's cutting-edge Steriwave nasal decolonisation technology, aimed at enhancing patient safety in essential markets.
Overview of the Partnership
This collaboration marks a crucial step in addressing the troubling increase of antimicrobial resistance (AMR) in healthcare. Steriwave provides a non-antibiotic, light-activated treatment that effectively targets the pathogens found in the nasal cavities, which are often a source of HAIs. By utilizing Steriwave, healthcare providers can significantly lower the risk of infections in patients while avoiding the amplification of drug resistance.
Mölnlycke's Contribution to Health Care
Mölnlycke, a key player in the MedTech market, specializes in developing advanced solutions for wound care and surgical needs. With operations in over 100 countries, their established networks and well-known brand position them ideally to accelerate the adoption of Steriwave technology.
Impact on the UK Market and Beyond
The initial focus of this partnership will be on the UK market, where Steriwave is already being integrated into various National Health Service (NHS) Trusts. Hospitals are keen to reduce infection rates, especially with over three million major surgeries and more than 200,000 intensive care unit admissions happening every year in the UK. Mölnlycke anticipates launching the Steriwave distribution by the end of 2024, with plans for expansion into Europe and the Middle East in 2025.
Advantages of Steriwave Technology
Steriwave therapy is unique in its ability to swiftly eradicate infection-causing bacteria in just five minutes. This rapid action considerably minimizes the chances for these pathogens to develop resistance. Hospitals that have started using Steriwave report high compliance rates from both staff and patients, highlighting the therapy's practicality and effectiveness.
Insights from Leadership
Lina Karlsson, Executive Vice President of Antiseptics at Mölnlycke, underscores the company’s sustainable mission to enhance patient care. She states, "By incorporating Steriwave into our product range, we are making a crucial move towards preventing HAIs and addressing the growing threat of antimicrobial resistance." This view is shared by Carolyn Cross, CEO of Ondine Biomedical, who points out that the partnership fits well with both organizations' commitment to transforming healthcare and elevating patient outcomes.
Tackling Global Healthcare Issues
Healthcare-associated infections remain an ongoing global issue, putting immense pressure on hospital resources and contributing to higher mortality rates. By advocating for strategies like nasal decolonization, Mölnlycke and Ondine intend to position Steriwave as a trustworthy alternative to conventional antibiotic treatments, aiding healthcare systems in their effort to lessen reliance on antibiotics.
Future Prospects
This partnership is not only focused on fulfilling immediate healthcare requirements but also emphasizes a sustainable approach to patient care. Mölnlycke's commitment to adopting innovative solutions like Steriwave illustrates a broader trend in the industry that prioritizes preventative measures to ensure patient safety while addressing the increasing problem of AMR.
Frequently Asked Questions
What is the purpose of Mölnlycke's collaboration with Ondine?
The partnership aims to distribute Steriwave nasal decolonisation technology to combat healthcare-associated infections and antimicrobial resistance.
How does Steriwave work?
Steriwave is a light-activated therapy that safely eliminates infection-causing bacteria in the nasal passages within a quick five-minute treatment.
Where will Steriwave be first implemented?
The initial market focus for Steriwave will be the UK, where it is already deployed in several NHS Trusts.
What impact do HAIs have on global healthcare?
HAIs are a significant challenge that result in increased healthcare costs, prolonged hospital stays, and higher rates of mortality.
When is the anticipated launch date for Steriwave in the UK?
Distribution of Steriwave in the UK is set to commence in the fourth quarter of 2024, with plans for further expansion in subsequent years.
